The DIT project : Drug induced thrombosis - a special focus on kinase and PARP inhibitors and

Medicine & Life Sciences

1. Protein-Tyrosine Kinases 100%
2. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 75%
3. ponatinib 67%
4. 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide 64%
5. Dasatinib 58%
6. Imatinib Mesylate 46%
7. Meta-Analysis 40%
8. Blood Vessels 30%
9. Survival 28%
10. Atherosclerosis 24%
11. Cell Survival 24%
12. Endothelial Cells 23%
13. Systematic Reviews 23%
14. Dacarbazine 20%
15. bosutinib 19%
16. Vinblastine 19%
17. Bleomycin 17%
18. Hodgkin Disease 16%
19. Odds Ratio 15%
20. Doxorubicin 14%
21. In Vitro Techniques 14%
22. Rupture 13%
23. Randomized Controlled Trials 10%
24. Biomarkers 10%
25. E-Selectin 10%
26. Vascular Cell Adhesion Molecule-1 9%
27. Safety 9%
28. Intercellular Adhesion Molecule-1 8%
29. Matrix Metalloproteinase 2 8%
30. Matrix Metalloproteinase 9 8%
31. Cell Movement 7%
32. Therapeutics 7%
33. Macrophages 6%
34. Leukemia, Myeloid, Chronic Phase 5%